In yesterday’s Wall Street session, Applied Therapeutics Inc. (NASDAQ:APLT) shares traded at $1.19, up 15.53% from the previous session.
3 analysts cover Applied Therapeutics Inc. (NASDAQ:APLT), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $23.00 and a low of $18.00, we find $20.50. Given the previous closing price of $1.03, this indicates a potential upside of 1890.29 percent. APLT stock price is now 36.87% away from the 50-day moving average and 1.01% away from the 200-day moving average. The market capitalization of the company currently stands at $57.19M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
The stock has received a hold rating from 0 analysts and a buy rating from 2. Brokers who have rated the stock have averaged $20.50 as their price target over the next twelve months.
With the price target reduced from $44 to $7, Barclays Downgraded its rating from Overweight to Equal Weight for Applied Therapeutics Inc. (NASDAQ: APLT). On August 27, 2021, Goldman Downgraded its previous ‘Neutral’ rating to ‘Sell’ on the stock reducing its target price from $16 to quote $10, while ‘Truist’ rates the stock as ‘Buy’.
In other news, Shendelman Shoshana, President and CEO sold 15,870 shares of the company’s stock on Jan 11. The stock was sold for $14,442 at an average price of $0.91. Upon completion of the transaction, the President and CEO now directly owns 751,625 shares in the company, valued at $0.89 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 11, Chief Medical Officer Perfetti Riccardo sold 6,053 shares of the business’s stock. A total of $5,508 was realized by selling the stock at an average price of $0.91. This leaves the insider owning 154,856 shares of the company worth $0.18 million. Insiders disposed of 300,905 shares of company stock worth roughly $0.36 million over the past 1 year. A total of 2.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in APLT stock. A new stake in Applied Therapeutics Inc. shares was purchased by PARAMETRIC PORTFOLIO ASSOCIATES LLC during the first quarter worth $32,000. PERENNIAL INVESTMENT ADVISORS, LLC invested $14,000 in shares of APLT during the first quarter. In the first quarter, MAN GROUP PLC acquired a new stake in Applied Therapeutics Inc. valued at approximately $13,000. AMALGAMATED FINANCIAL CORP. acquired a new stake in APLT for approximately $3,000. CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. purchased a new stake in APLT valued at around $1,000 in the second quarter. In total, there are 82 active investors with 57.10% ownership of the company’s stock.
On Monday morning Applied Therapeutics Inc. (NASDAQ: APLT) stock kicked off with the opening price of $1.1000. During the past 12 months, Applied Therapeutics Inc. has had a low of $0.50 and a high of $3.49. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.20, and a quick ratio of 1.20. The fifty day moving average price for APLT is $0.8695 and a two-hundred day moving average price translates $1.1781 for the stock.
The latest earnings results from Applied Therapeutics Inc. (NASDAQ: APLT) was released for Jun, 2022.
Applied Therapeutics Inc.(APLT) Company Profile
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
